Overview

A Clinical Study of MIL93 in Solid Tumors.

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

MIL93 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open label Phase I study to evaluate safety, tolerability, pharmacokinetics and efficacy of MIL93 in Advanced or Metastatic solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Beijing Mabworks Biotech Co., Ltd.

Treatments:

Antibodies
Antibodies, Monoclonal